Acrodermatitis chronica atrophicans epidemiology and demographics: Difference between revisions
(→Gender) |
(→Age) |
||
| Line 21: | Line 21: | ||
===Age=== | ===Age=== | ||
*The [[incidence]] of [[acrodermatitis chronica atrophicans]] increases with [[aging|age]]. <ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153 }} </ref> | *The [[incidence]] of [[acrodermatitis chronica atrophicans]] increases with [[aging|age]]. <ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153 }} </ref> | ||
*[[Acrodermatitis chronica atrophicans]] commonly affects individuals in range of 40 to 70 years old.<ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153 }} </ref> | |||
*There are few [[case report|case reports]] on [[child|children]] who are [[diagnosis|diagnosed]] with [[acrodermatitis chronica atrophicans]]. | |||
===Race=== | ===Race=== | ||
Revision as of 10:43, 3 June 2021
|
Acrodermatitis chronica atrophicans Microchapters |
|
Differentiating Acrodermatitis chronica atrophicans from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acrodermatitis chronica atrophicans epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans epidemiology and demographics |
|
FDA on Acrodermatitis chronica atrophicans epidemiology and demographics |
|
CDC on Acrodermatitis chronica atrophicans epidemiology and demographics |
|
Acrodermatitis chronica atrophicans epidemiology and demographics in the news |
|
Blogs on Acrodermatitis chronica atrophicans epidemiology and demographics |
|
Xyz Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Acrodermatitis chronica atrophicans epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans epidemiology and demographics |
|
FDA on Acrodermatitis chronica atrophicans epidemiology and demographics |
|
CDC on Acrodermatitis chronica atrophicans epidemiology and demographics |
|
Acrodermatitis chronica atrophicans epidemiology and demographics in the news |
|
Blogs on Acrodermatitis chronica atrophicans epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]
Overview
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- The incidence of acrodermatitis chronica atrophicans increases with age. [1]
- Acrodermatitis chronica atrophicans commonly affects individuals in range of 40 to 70 years old.[1]
- There are few case reports on children who are diagnosed with acrodermatitis chronica atrophicans.
Race
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- Acrodermatitis chronica atrophicans affects women more than men.[1]
- Based on several studies female predominance has been reported approximately 65% and 80% in acrodermatitis chronica atrophicans patient.[2][3][4]
Region
- The majority of acrodermatitis chronica atrophicans cases are reported in northern, central and eastern Europe. [1]
- Lately few cases of acrodermatitis chronica atrophicans have been reported in the United States which were associated to Lyme disease (besides European immigrants). [1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Khalili M, Wong RJ (2018). "Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net". Dig Dis Sci. 63 (12): 3250–3252. doi:10.1007/s10620-018-5316-9. PMC 6436636. PMID 30311153.
- ↑ THYRESSON N (1949). "The penicillin treatment of acrodermatitis atrophicans chronica (Herxheimer)". Acta Derm Venereol. 29 (6): 572–621. PMID 18140373.
- ↑ Asbrink E, Hovmark A, Olsson I (1986). "Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients". Zentralbl Bakteriol Mikrobiol Hyg A. 263 (1–2): 253–61. doi:10.1016/s0176-6724(86)80128-6. PMID 3577484.
- ↑ Weber K, Preac-Mursic V, Neubert U, Thurmayr R, Herzer P, Wilske B; et al. (1988). "Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans". Ann N Y Acad Sci. 539: 324–45. doi:10.1111/j.1749-6632.1988.tb31867.x. PMID 3056202.